Business Wire

Synaffix Announces License Agreement with Mersana Therapeutics for the Use of its GlycoConnect™ Site-Specific ADC Technology

AMSTERDAM--(BUSINESS WIRE)--Synaffix B.V. announced today it has entered into a license agreement with Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and ...
Nature

Hitting the antibody–drug conjugate sweet spot

Synaffix’s glycan-based antibody–drug conjugate technology is experiencing strong demand, based on its potential to improve safety and efficacy of cancer therapies without genetic engineering.
Nasdaq

Synaffix Inks Deal with MacroGenics to Enable Next Generation ADCs

AMSTERDAM, Feb. 3, 2022 /PRNewswire/ -- Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) ...
DutchNews.NL

Synaffix announces expansion of license agreement with Shanghai Miracogen Inc. to a second ADC candidate

Expansion of existing deal with leading Chinese ADC developer Total of six partnered ADCs based on Synaffix’s proprietary GlycoConnect™ and HydraSpace™ ADC technologies now under development AMSTERDAM ...
elEconomista

Abzena Announces Successful Technical Transfer of Synaffix GlycoConnect? Antibody Drug Conjugate (ADC) Technology to Enable Use in Client Projects

Abzena, the global partner research organization, announced it has successfully completed a technology transfer and scalability evaluation using the Synaffix technologies of GlycoConnect™ (antibody ...
Business Wire

Synaffix announces expansion of license agreement with Shanghai Miracogen Inc. to a second ADC candidate

AMSTERDAM--(BUSINESS WIRE)--Synaffix B.V., a biotechnology company focused on enabling antibody-drug conjugates (ADCs) with superior therapeutic index based on its proprietary ADC technologies, ...